Keros Therapeutics, Inc. (KROS) Earnings Call Transcripts

Keros Therapeutics, Inc.'s Latest Earnings Call - June 8, 2026

In the Q2 2026 earnings call, Keros Therapeutics, Inc. (KROS:US) focused on its development programs targeting Duchenne Muscular Dystrophy (DMD) and Amyotrophic Lateral Sclerosis (ALS). The company reported a cash balance of $282 million, providing a runway into H1 2028, which is crucial for advancing its clinical trials. Management emphasized the unique positioning of its lead candidate, renvatrercept, in a competitive landscape, stating it 'can provide additional benefit' alongside existing therapies. No revenue or earnings figures were disclosed, and guidance remains unchanged as they continue to progress in their clinical trials.

Reported metrics

Guidance from management

Management maintained guidance for ongoing clinical trials and indicated that they will provide updates as data becomes available, particularly in 2027.

What management said

Yes, I think, first of all, -- we are a company that's been focused on TGF-beta biology. And it's a complex area of biology. -- but we've been working in it through various iterations for the last 25-plus years. So I think we have a deep understanding that is unique to us in terms of what's druggable -- and what are the indications that you can target? And when it comes to the remainder of core competencies, clinical...

Yes. So like many other tissues, the TGF-beta pathway is involved in differentiation. So it's really involved in both self renewal of stem cells that then go on to populate the tissue, that happened during embryogenesis. But in the adult, these this pathway is constantly involved in generating new differentiated cells to replace the ones that are aging, okay, and therefore, ready on their path to senescence.

What analysts pressed on

Analysts expressed concerns about the competitive landscape in DMD and the challenges associated with demonstrating functional benefits in clinical trials. There were questions about the timelines for achieving meaningful clinical endpoints and how Keros plans to differentiate its therapies from existing treatments.

Main topics on the call

• Focus on DMD Development — Keros is pivoting back to focus on DMD, citing its potential to increase muscle strength and energy expenditure. Management stated, 'you can get to an endpoint in 12 months' for DMD trials, highlighting the strategic tim...
• Cash Position and Runway — The company reported a cash balance of $282 million, which supports operations into H1 2028. This strong cash position allows Keros to fund ongoing clinical trials without immediate financial pressure.
• Clinical Trial Design for DMD — Management outlined the design for the Phase II trial, focusing on late ambulatory boys with DMD to demonstrate stabilization or improvement in muscle function. They noted that 'you want to pick a cohort that is in the l...
• Partnership with Takeda — Keros has partnered with Takeda for elrintercept, receiving $200 million upfront and potential milestones totaling $1.1 billion. Management highlighted that Takeda is actively recruiting for multiple Phase III trials, in...

Read the full Keros Therapeutics, Inc. transcript (June 8, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 5 Keros Therapeutics, Inc. earnings call transcripts on record, spanning February 24, 2021 to June 8, 2026. Based on this history, Keros Therapeutics, Inc. reports annually. The most recent call on file is dated June 8, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

KROS

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

5

First call

February 24, 2021

Most recent

June 8, 2026

Reporting cadence

annually